Grant Life Sciences, Inc. Announces New Stock Symbol and Name Change
November 15 2004 - 4:29PM
PR Newswire (US)
Grant Life Sciences, Inc. Announces New Stock Symbol and Name
Change SALT LAKE CITY, Nov. 15 /PRNewswire-FirstCall/ -- Grant Life
Sciences, Inc., [OTC Bulletin Board: GLIF] announced the Company's
common stock symbol has changed from OTCBB: GRTV to OTCBB: GLIF
effective at the opening of the market tomorrow, November 16, 2004.
This coincides with the Company's name change from Grant Ventures,
Inc. to Grant Life Sciences, Inc. Stan Yakatan, CEO and Chairman of
Grant Life Sciences, stated, "This ticker and name change was done
to better reflect our ongoing business focused on the area of life
sciences and diagnostics. Our current lead program is the
development of a more efficient test for the diagnosis of cervical
cancer. We are very excited about this non-invasive, blood test to
screen woman, that could be potentially used as an adjunct to a Pap
smear in developed nations and also to target the 1.7 billion women
globally who have never received a Pap smear for cultural,
religious or economic reasons." About Grant Life Sciences, Inc.
Grant Life Sciences, Inc. develops products to improve the
efficiency of diagnosing cervical cancer. The Company currently is
developing protein-based screening tests to screen woman for
cervical cancer and pre-cancerous conditions. This screening test
analyzes blood for the presence of certain antibodies that appear
only when cervical cancer or certain pre-cancerous conditions are
present. Invasive cervical cancer kills approximately 300,000 women
annually. Currently, there are more than 120 million cervical
screening tests administered annually in the United States and
Europe. More than 120 million eligible women 20+ years old in
developed nations still do not get Pap smears and globally 1.7
billion women over the age of 20 do not undergo regular cervical
cancer testing. Forward-Looking Safe Harbor Statement: This press
release contains forward-looking statements. By their nature,
forward-looking statements and forecasts involve risks and
uncertainties because they relate to events and depend on
circumstances that will occur in the future. There are a number of
factors that could cause actual results and developments to differ
materially. For a discussion of those risks and uncertainties,
please see our filings with the Securities and Exchange Commission.
DATASOURCE: Grant Life Sciences, Inc. CONTACT: Stan Yakatan, Chief
Executive Officer of Grant Life Sciences, +1-310-374-0808; or Brian
Korb, Senior Associate of The Trout Group, +1-212-477-9007 x23
Copyright